Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068715 · ClinicalTrials.gov registry record · NA
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03068715: Completed NA study, sponsored by Stanford University.
NCT03068715 is a NA study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03068715, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.
Interventions
- DEVICE Active TBS-DLPFC
- DEVICE Sham TBS-DLPFC
- DEVICE Open label TBS-DLPFC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2021-01-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068715
The ClinicalTrials.gov registry entry for NCT03068715 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Active TBS-DLPFC is the first listed.
NCT03068715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068715 about?
NCT03068715 is a clinical study titled "Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)". This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.
What is the current status of trial NCT03068715?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-03-20. Estimated completion is 2021-01-09.
What interventions are being tested in trial NCT03068715?
The interventions under investigation include: Active TBS-DLPFC (DEVICE), Sham TBS-DLPFC (DEVICE), Open label TBS-DLPFC (DEVICE).
Who is sponsoring clinical trial NCT03068715?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.